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Background & objectives: The aim of the present study is to investigate the physicochemical
equivalence of seven brands of tablets containing chloroquine phosphate, an antimalarial purchased
from different retail pharmacy outlets.
Methods: The quality and physicochemical equivalence of seven different brands of chloroquine
phosphate tablets were assessed. The assessment included the evaluation of uniformity of weight,
friability, crushing strength, disintegration and dissolution tests as well as chemical assay of the
tablets.
Results: All the seven brands of the tablets passed the British Pharmacopoeia (BP) standards for
uniformity of weight, disintegration and crushing strength. One of seven brands failed the friability
test. One of the brands did not comply with the standard assay of content of active ingredients.
Dissolution test passes the pharmacopoeial standards for chloroquine phosphate tablets. There were
no significant differences in the amounts of chloroquine phosphate released from the different brands.
Interpretation & conclusion: Out of the seven brands of anti-malarial chloroquine phosphate tablets
only one brand fails to meet BP quality specifications which shows constant market monitoring of
new products to ascertain their equivalency to pharmacopoeial standards.
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The increase in the number of generic drug products
from multiple sources has placed people involved in
the delivery of health care in a position of having to
select one among several seemingly equivalent prod-
ucts. For instance, in 1975 approximately 9% of all
prescription drugs dispensed in the United States
were generic versions1. This figure rose to 20% in
1984 and 40% in 19912. Over 80% of the approxi-
mately 10,000 prescription drugs available in 1990
were obtained from more than one source and vari-
able clinical responses to these dosage forms supplied
by two or more drug manufacturers is documented2.
These variable responses may be due to formulation
ingredients employed, methods of handling, packaging
and storage and even the rigours of in-process quality
control. Thus, there is need to determine their phar-
maceutical and therapeutic equivalence in order to en-
sure interchangeability.
However, many developing countries do not have an
effective means of monitoring the quality of generic
drug products in the market. This results in wide-
spread distribution of substandard and/or counterfeit
drug products. It was in view of this fact that the
World Health Organization issued guidelines for global
standard and requirements for the registration, assess-J  VECT  BORNE  DIS  42,  DECEMBER  2005 148
ment, marketing, authorisation and quality control of
generic pharmaceutical products3. Generic drug prod-
ucts must satisfy the same standards of quality, effica-
cy and safety as those applicable to the innovator
products. Preliminary physicochemical assessment of
the products is very important and in vitro dissolution
testing can be a valuable predictor of the in vivo bio-
availability and bioequivalence of oral solid dosage
forms4.
Chloroquine phosphate is a 4-aminoquinoline com-
pound for oral administration. It is 7-chloro-4-{[4-(di-
ethyl amino)-1-methylbutyl] amino]} quinoline phos-
phate (1:2) and has the following structural formula:
Physical measurements: Twenty tablets selected at
random were weighed individually and their average
weight calculated to determine the weight uniformity5
and percentage deviation of each tablet from the aver-
age weight was determined. The pre-weighed twenty
tablet sample was placed in the friabilator (HICON)
and weight loss was determined as a percentage of
the initial weight. Crushing strength of each of nine
tablets per brand was performed by using Pfizer hard-
ness tester [Pfizer-HICON hardness tester]. The dis-
integration test ((DT-HICON)), dissolution test
[Electrolab (USP, TDT-06T)] and assay (Spectro-
photometry Shimadzu 1700) of all tablets were car-
ried out as per USP’20026.
Data analysis: Data for weight uniformity test, friabil-
ity, crushing strength and the disintegration and disso-
lution times of the tablets were analysed by determin-
ing the mean ± standard deviation.
Results & Discussion
The results of the physicochemical properties of the
various brands of chloroquine phosphate are pre-
sented in Table 1. All brands showed acceptable uni-
formity of weight as none had percent deviation in
weight > 5% as stipulated by the British Pharmaco-
poeia 19985. The significance of this test is to ensure
that the tablets in each lot are within the appropriate
size range.
The crushing strength of the tablets is an essential cri-
terion in the determination of the ability of the tablets
to resist chipping, abrasion or breakage under condi-
tions of storage, transportation and handling before
storage. The results showed that the brands examined
had mean crushing strength within the range of 4.87–
8.45 kg/cm2.
Another tablet property related to crushing strength is
friability, which is designed to evaluate the ability of
the tablet to withstand abrasion during packaging,
handling and shipping. For compressed tablets, per-
centage loss in weight of less than 1% is usually con-
NHCH(CH2)3N(C2H5)2
CH3
Cl N
 
(H3PO4) 2 .
Chloroquine is rapidly and almost completely absorbed
from the gastrointestinal tract. It is indicated for the sup-
pressive treatment and for acute attacks of malaria due
to Plasmodium vivax, P. malariae, P. ovale, and
susceptible strains of P. falciparum. The drug is also
indicated for the treatment of extraintestinal amoebiasis.
Thus, in the present study the equivalence of seven
brands of chloroquine phosphate tablets sourced from
retail pharmacies from North Gujarat were deter-
mined using in vitro methods. This preliminary study
is aimed at obtaining baseline data towards the estab-
lishment of bioequivalence of the tablets.
Material & Methods
Seven brands of chloroquine phosphate tablets (A to
G) were obtained from different retail outlets in north
Gujarat. All the products were manufactured within six
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sidered acceptable7. The results showed that brands
A, B, C, D, F and G conformed to the required stan-
dard for friability, while brand E failed to comply. This
failure could have resulted from the use of inadequate
or insufficient amount of binding agent during formula-
tion, inadequate moisture content during compression
or insufficient compression pressure during tableting.
The disintegration test measures the time required for
tablets to disintegrate into particles. This is a necessary
condition for dissolution and could be the rate-deter-
mining step in the process of drug absorption. The BP
1998 stipulates a disintegration time of not more 15
min for uncoated tablets. The results of the disintegra-
tion test are presented in Table 1. The results showed
that all the brands passed the disintegration test.
The results of the assays of chemical content to deter-
mine the amount of chloroquine phosphate present in
each formulation are presented in Table 1. Except
brand E all the brands contain between 92.5 and
107.5% of the labeled amount specified for chloro-
quine phosphate. Low content in brand may be due to
poor preparation techniques during formulation and
subsequent manufacturing.
The dissolution test is a measure of the amount of the
drug released into the dissolution medium with time.
The United States Pharmacopoeia stipulates that at 30
min, all tablets should have released into the dissolu-
tion medium an amount not less than 60% of the la-
beled amount of chloroquine phosphate. All the brands
passed the dissolution test.
Conclusion
Only one brand of antimalarial chloroquine phosphate
failed to meet the requirement according to pharmaco-
poeia and all other brands of chloroquine phosphate
passed the standards. This study highlights the need
for constant market monitoring of new products to as-
certain their equivalency to pharmacopoeial standards.
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